Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Visit the company website

 

Stock Quote Today & Recent News Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Opinion & Analysis (TSXV:VM)

Progress for radiology drugs and medical imaging company

Shoran Devi June 12, 2023

Health Canada Approvals Set Stage for Revenue Generation

Dave Jackson February 25, 2021

From the Earth to the Bottle

Dave Jackson January 21, 2020

VIDEO: High Grade Barite Producer

BTV-Business Television May 18, 2017

Bullboard Posts (TSXV:VM)

RE:New Press Release - Voyageur Advances MRI Drug Development Using Next Generation Endohedral Fullerenes

Global MRI Contrast Media Market Size To Exceed USD 2.35 Billion By 2033 | CAGR Of 4.59% https://www.globenewswire.com/news-release...
lscfa - 5 hours ago

RE:now ask me

I fully agree with you postie 1. Several comments made on this site make me believe that my last prediction said a few days ago was not...
Budlight1971 - 6 hours ago

now ask me

why I think VM has a large  target on its'back and is a prime candidate for that by more than just the contrast players. I think...
postie1 - 7 hours ago

RE:RE:Finally, It Has Begun

    $1 mil budget 1st tranche 2nd tranche ...
lscfa - 9 hours ago

RE:Finally, It Has Begun

It took the exercise of those warrants to get enough funding for the fullerene R&D which was budgeted at $200,000
lscfa - 9 hours ago

Finally, It Has Begun

Voyageur is set to become a significant player in the biotech industry with its development of next-generation radiology drugs. The...
biggdogg - 10 hours ago

Connect with V.VM

follow v.vm on


The Watchlist

Voyageur Pharmaceuticals | The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

COMPELLING
VALUE PROPOSITION

  • Only pharmaceutical company in the world that owns long-term supply of barium and iodine
  • Natural barium and iodine resources meet increasingly limited global supply and risk
  • Multi-billion-dollar global market for contrast media
  • Poised to obtain significant market share by offering high-quality, lower-cost products
  • Favorable regulatory pathway allows rapid commercialization
  • Highly experienced team has positioned the company for profitable commercial success

Contact Us

Brent Willis, CEO
Brent@Vpharma.ca

Address:
Suite 1600 Dome Tower, 333 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1